Rogers ROG
- Market cap
- $2.2B
- PE
- 71.4×
- 10y median 34.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.7×
- EV/EBIT
- 16.3×
- Revenue, 12 months
- $834.8M
- +5% on a year ago
- Net margin
- 3.7%
- Free cash flow yield
- 3.7%
Rogers trades at 71.4× trailing earnings, pricier than 88% of the last ten years. Revenue was $834.8M over the last twelve months, up 5% on a year earlier with a 4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $229.1M−7% | $204.6M−9% | $213.4M−13% | $214.2M−7% | $210.3M−8% | $192.2M−6% | $190.5M−11% | $202.8M−5% | $216M+3% | $201.5M+5% | $200.5M+5% | $216.8M+7% | |
| Cost of revenue | $148.7M−12% | $137.2M−10% | $145.2M−12% | $141.1M−7% | $136.2M−8% | $130.5M−5% | $133.5M−8% | $138.8M−2% | $143.7M+6% | $138M+6% | $135.9M+2% | $146.4M+6% |
| Gross profit | $80.4M+3% | $67.4M−5% | $68.2M−14% | $73.1M−8% | $74.1M−8% | $61.7M−9% | $57M−16% | $64M−12% | $72.3M−2% | $63.5M+3% | $64.6M+13% | $70.4M+10% |
| R&D | $7.8M−14% | $10.2M+4% | $8.9M−7% | $9.5M+17% | $8.1M+4% | $8.1M−21% | $7.1M−20% | $7M−26% | $7.4M−9% | $6.6M−19% | $6.7M−6% | $7.3M+4% |
| SG&A | $44.2M−13% | $51.8M−5% | $47.5M−21% | $50.9M+10% | $45.1M+2% | $49.9M−4% | $44.5M−6% | $48.5M−5% | $41.6M−8% | $42M−16% | $41.2M−7% | $42.2M−13% |
| $27.2M+47% | $30.5M−63% | $11.7M | $11.3M−60% | $14.6M−46% | −$12.7M | −$300K | −$67.5M | $15.7M+8% | $7.1M | $10.7M | $20M | |
| Interest expense | −$2.3M | $18.7M+369% | $800K−77% | $200K−93% | $0 | $1.8M−90% | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $26.2M+48% | $28.6M−64% | $11.6M | $11.9M−53% | $13.5M−49% | −$2.7M | −$1.6M | −$69.3M | $16.3M+21% | $9.5M | $11.3M | $21.4M |
| $7.2M+153% | $5.4M−51% | $3.8M | $3.8M−47% | $2.8M−61% | −$2.2M | −$200K | $4.3M+13% | $7.7M+175% | $4.9M | $6.8M | $7.8M+81% | |
| Net income | $19M+28% | $23.2M−66% | $7.8M | $8.1M−55% | $10.7M−44% | −$500K | −$1.4M | −$73.6M | $8.6M−20% | $4.6M | $4.5M | $13.6M |
| $1.02+31% | $1.23−66% | $0.42 | $0.44−54% | $0.58−43% | −$0.03 | −$0.08 | −$4.00 | $0.48−17% | $0.26 | $0.25 | $0.76 | |
| 18.7M−2% | 18.8M−0% | 18.7M+1% | 18.6M−0% | 18.6M−1% | 18.6M−1% | 18.5M−1% | 18.4M−1% | 18.1M−3% | 17.9M−4% | 17.9M−3% | 18M−2% |
EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY19 and Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest Rogers' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ROGRogers | $2.2B | 71.4× | 34.3× | 2.7× | +5% | 3.7% | |
| NGVTIngevity | $2.4B | 47.4× | 19.9× | 2.1× | −4% | 4.7% | |
| IOSPInnospec | $2.4B | 20.1× | 22.3× | 1.3× | +3% | 6.6% | |
| FULFuller H B | $2.7B | 13.8× | 22.9× | 0.8× | +1% | 5.6% | |
| WDFCWD 40 | $2.9B | 32.3× | 39.2× | 4.2× | +10% | 13.2% | |
| AVNTAvient | $3.8B | 22.2× | 20.2× | 1.1× | +2% | 5.1% | |
| CBTCabot | $3.8B | 20.8× | 14.4× | 1.0× | −5% | 5.2% | |
| CRONCronos | $1.2B | 16.8× | 25.0× | 6.9× | +37% | 39.1% | |
| CSWCSW Industrials | $4.8B | 40.6× | 34.7× | 4.1× | +28% | 10.3% | |
| BCPCBalchem | $5.6B | 34.8× | 41.0× | 5.2× | +9% | 15.1% | |
| FTKFlotek Industries | $865.7M | 24.1× | 27.6× | 3.0× | +37% | 13.0% | |
| Peer median | $2.8B | 23.2× | 23.9× | 2.5× | +6% | 8.5% |
Investors who own it
Investors we follow who held Rogers at the end of Jun 30, 2026, from their 13F filings.
- Gavin BakerAtreides Management0.3% of portfolioadded
More on Rogers
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .